For decades, osteoporosis has meant a slow, one way slide toward fragile bones and fracture risk, managed but rarely truly ...

This article was originally on a blog post platform and may be missing photos, graphics or links. See About archive blog posts. In a long-awaited development, the first drug in a new class of ...

Amgen (NASDAQ:AMGN) announced new data supporting its FDA-approved osteoporosis therapy Prolia (Denosumab) on Monday, highlighting its potential against oral alendronate, a commonly-used medication to ...

The surrogate endpoint offers an alternative to traditional fracture endpoints used in clinical trials of osteoporosis drugs ...

The FDA has added a serious warning to the prescribing information for Amgen Inc’s (NASDAQ:AMGN) drug Prolia (denosumab), emphasizing an increased risk of severely low calcium levels in specific ...

Original Medicare (Part A and Part B), Part D, and Medicare Advantage typically offer coverage for the osteoporosis drug Prolia. However, individuals must meet certain requirements for Part B coverage ...

The FDA greenlights treatment-related changes in bone mineral density as a surrogate endpoint in anti-osteoporosis drug trials in postmenopausal women.

Approvals expand Amneal’s biosimilars portfolioCompany expects to commercialize six biosimilars across eight presentations by 2027BRIDGEWATER, ...

Continued treatment with the osteoporosis drug denosumab (Prolia) was tied to a lower risk of developing diabetes in a Taiwanese cohort study. In a propensity score-matched analysis, adherence to ...

Amgen Inc. raises 2025 revenue guidance on strong Repatha and Imdelltra sales and dividend hike. Click for this AMGN update.